U.S. FDA faces mounting criticism over Alzheimer’s drug approval

In approving the first new Alzheimer’s drug, the U.S. FDA is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, experts say.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.